ADME-Tox Screening Systems Comprehensive Study by Type (Instruments, Assay system, Software), Application (Discovery and Development, Biopharmaceutical Production, Drug Screening, Tissue Engineering, Others), Technology (Cell culture, Ultra ADME toxicology), End User (Biopharmaceutical Companies, Contract Research Organization (CRO’s), Academic and Research Institute, Others) Players and Region - Global Market Outlook to 2027

ADME-Tox Screening Systems Market by XX Submarkets | Forecast Years 2022-2027 | CAGR: 10.3%  

  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
ADME-Tox Screening Systems Market Scope
ADME-Tox screening systems' goal is to provide a more complete understanding of the effects a molecule might have on the entire biological systemThe increasing focus of drug manufacturers to reduce the development cost of drugs with the least toxicological issue is the major driving factor of the ADME-Tox screening system market. Apart from that, the ADME-Toxicological testing increases the potential of the drug which increases the efficiency of the drug to target the desired tissue. Moreover, the rising prevalence of various chronic diseases is increasing the demand for specialized drugs will upsurge the growth of the AME-Tox screening system market.

AttributesDetails
Study Period2017-2027
Base Year2021
High Growth MarketChina
Largest MarketNorth America
UnitValue (USD Million)
Key Companies ProfiledHudson Robotics, Inc (United States), ACEA Biosciences Inc. (United States), Agilent Technologies, Inc. (United States), ADMEcell (United States), Albany Molecular Research Inc. (United States), BioreclamationIVT, LLC (United States), Beckman Coulter Inc. (United States), Cerep SA (France), Cyprotex (United Kingdom) and Labcyte Inc. (United States)
CAGR10.3%


The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Research Analyst at AMA estimates that United States Players will contribute to the maximum growth of Global ADME-Tox Screening Systems market throughout the predicted period.

Hudson Robotics, Inc (United States), ACEA Biosciences Inc. (United States), Agilent Technologies, Inc. (United States), ADMEcell (United States), Albany Molecular Research Inc. (United States), BioreclamationIVT, LLC (United States), Beckman Coulter Inc. (United States), Cerep SA (France), Cyprotex (United Kingdom) and Labcyte Inc. (United States) are some of the key players that are part of study coverage.

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from the total available market.

Segmentation Overview
The study have segmented the market of Global ADME-Tox Screening Systems market by Type , by Application (Discovery and Development, Biopharmaceutical Production, Drug Screening, Tissue Engineering and Others) and Region with country level break-up.

On the basis of geography, the market of ADME-Tox Screening Systems has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). North America region held largest market share in the year 2021.

Market Leaders and their expansionary development strategies
In July 2018, BioIVT, a leading provider of research models and services for drug development, today announced that it has acquired Santa Clara, CA-based Optivia Biotechnology and its comprehensive portfolio of transporter assays, multi-transporter models, transporter systems biology, and molecular transport research solutions.



ADME-Tox Screening Systems Market Dynamics:
AttributesDetails
Trends Influencing Market
  • Technological Advancements in ADME-Tox Screening System
Key Restraints
  • High Installation and Maintenance Cost of the System
Challenges
  • Lack of Skilled Professional to Operate System
Market Opportunities
  • Increased Drug Development and Biopharmaceutical Production
  • Ongoing R&D in the Field of ADME-Tox Screening Systems


Key Target Audience
New Entrants/Investors, Analysts and Strategic Business Planners, ADME-Tox Screening Systems Provider, Venture Capitalists and Private Equity Firms, Government Regulatory and Research Organizations and End-Use Industry

Report Objectives / Segmentation Covered

By Type
  • Instruments
  • Assay system
  • Software
By Application
  • Discovery and Development
  • Biopharmaceutical Production
  • Drug Screening
  • Tissue Engineering
  • Others
By Technology
  • Cell culture
  • Ultra ADME toxicology

By End User
  • Biopharmaceutical Companies
  • Contract Research Organization (CRO’s)
  • Academic and Research Institute
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Focus of Drug Manufacturer to Reduce the Development Cost of Drug with Least Toxicological Issue
      • 3.2.2. Rising Demand for Specialized Drug due to Prevalence of various Chronic Diseases
    • 3.3. Market Challenges
      • 3.3.1. Lack of Skilled Professional to Operate System
    • 3.4. Market Trends
      • 3.4.1. Technological Advancements in ADME-Tox Screening System
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global ADME-Tox Screening Systems, by Type, Application, Technology , End User and Region (value and price ) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global ADME-Tox Screening Systems (Value)
      • 5.2.1. Global ADME-Tox Screening Systems by: Type (Value)
        • 5.2.1.1. Instruments
        • 5.2.1.2. Assay system
        • 5.2.1.3. Software
      • 5.2.2. Global ADME-Tox Screening Systems by: Application (Value)
        • 5.2.2.1. Discovery and Development
        • 5.2.2.2. Biopharmaceutical Production
        • 5.2.2.3. Drug Screening
        • 5.2.2.4. Tissue Engineering
        • 5.2.2.5. Others
      • 5.2.3. Global ADME-Tox Screening Systems by: End User (Value)
        • 5.2.3.1. Biopharmaceutical Companies
        • 5.2.3.2. Contract Research Organization (CRO’s)
        • 5.2.3.3. Academic and Research Institute
        • 5.2.3.4. Others
      • 5.2.4. Global ADME-Tox Screening Systems Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global ADME-Tox Screening Systems (Price)
      • 5.3.1. Global ADME-Tox Screening Systems by: Type (Price)
  • 6. ADME-Tox Screening Systems: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Hudson Robotics, Inc (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. ACEA Biosciences Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Agilent Technologies, Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. ADMEcell (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Albany Molecular Research Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. BioreclamationIVT, LLC (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Beckman Coulter Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Cerep SA (France)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Cyprotex (United Kingdom)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Labcyte Inc. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global ADME-Tox Screening Systems Sale, by Type, Application, Technology , End User and Region (value and price ) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global ADME-Tox Screening Systems (Value)
      • 7.2.1. Global ADME-Tox Screening Systems by: Type (Value)
        • 7.2.1.1. Instruments
        • 7.2.1.2. Assay system
        • 7.2.1.3. Software
      • 7.2.2. Global ADME-Tox Screening Systems by: Application (Value)
        • 7.2.2.1. Discovery and Development
        • 7.2.2.2. Biopharmaceutical Production
        • 7.2.2.3. Drug Screening
        • 7.2.2.4. Tissue Engineering
        • 7.2.2.5. Others
      • 7.2.3. Global ADME-Tox Screening Systems by: End User (Value)
        • 7.2.3.1. Biopharmaceutical Companies
        • 7.2.3.2. Contract Research Organization (CRO’s)
        • 7.2.3.3. Academic and Research Institute
        • 7.2.3.4. Others
      • 7.2.4. Global ADME-Tox Screening Systems Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global ADME-Tox Screening Systems (Price)
      • 7.3.1. Global ADME-Tox Screening Systems by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. ADME-Tox Screening Systems: by Type(USD Million)
  • Table 2. ADME-Tox Screening Systems Instruments , by Region USD Million (2016-2021)
  • Table 3. ADME-Tox Screening Systems Assay system , by Region USD Million (2016-2021)
  • Table 4. ADME-Tox Screening Systems Software , by Region USD Million (2016-2021)
  • Table 5. ADME-Tox Screening Systems: by Application(USD Million)
  • Table 6. ADME-Tox Screening Systems Discovery and Development , by Region USD Million (2016-2021)
  • Table 7. ADME-Tox Screening Systems Biopharmaceutical Production , by Region USD Million (2016-2021)
  • Table 8. ADME-Tox Screening Systems Drug Screening , by Region USD Million (2016-2021)
  • Table 9. ADME-Tox Screening Systems Tissue Engineering , by Region USD Million (2016-2021)
  • Table 10. ADME-Tox Screening Systems Others , by Region USD Million (2016-2021)
  • Table 11. ADME-Tox Screening Systems: by End User(USD Million)
  • Table 12. ADME-Tox Screening Systems Biopharmaceutical Companies , by Region USD Million (2016-2021)
  • Table 13. ADME-Tox Screening Systems Contract Research Organization (CRO’s) , by Region USD Million (2016-2021)
  • Table 14. ADME-Tox Screening Systems Academic and Research Institute , by Region USD Million (2016-2021)
  • Table 15. ADME-Tox Screening Systems Others , by Region USD Million (2016-2021)
  • Table 16. South America ADME-Tox Screening Systems, by Country USD Million (2016-2021)
  • Table 17. South America ADME-Tox Screening Systems, by Type USD Million (2016-2021)
  • Table 18. South America ADME-Tox Screening Systems, by Application USD Million (2016-2021)
  • Table 19. South America ADME-Tox Screening Systems, by Technology USD Million (2016-2021)
  • Table 20. South America ADME-Tox Screening Systems, by End User USD Million (2016-2021)
  • Table 21. Brazil ADME-Tox Screening Systems, by Type USD Million (2016-2021)
  • Table 22. Brazil ADME-Tox Screening Systems, by Application USD Million (2016-2021)
  • Table 23. Brazil ADME-Tox Screening Systems, by Technology USD Million (2016-2021)
  • Table 24. Brazil ADME-Tox Screening Systems, by End User USD Million (2016-2021)
  • Table 25. Argentina ADME-Tox Screening Systems, by Type USD Million (2016-2021)
  • Table 26. Argentina ADME-Tox Screening Systems, by Application USD Million (2016-2021)
  • Table 27. Argentina ADME-Tox Screening Systems, by Technology USD Million (2016-2021)
  • Table 28. Argentina ADME-Tox Screening Systems, by End User USD Million (2016-2021)
  • Table 29. Rest of South America ADME-Tox Screening Systems, by Type USD Million (2016-2021)
  • Table 30. Rest of South America ADME-Tox Screening Systems, by Application USD Million (2016-2021)
  • Table 31. Rest of South America ADME-Tox Screening Systems, by Technology USD Million (2016-2021)
  • Table 32. Rest of South America ADME-Tox Screening Systems, by End User USD Million (2016-2021)
  • Table 33. Asia Pacific ADME-Tox Screening Systems, by Country USD Million (2016-2021)
  • Table 34. Asia Pacific ADME-Tox Screening Systems, by Type USD Million (2016-2021)
  • Table 35. Asia Pacific ADME-Tox Screening Systems, by Application USD Million (2016-2021)
  • Table 36. Asia Pacific ADME-Tox Screening Systems, by Technology USD Million (2016-2021)
  • Table 37. Asia Pacific ADME-Tox Screening Systems, by End User USD Million (2016-2021)
  • Table 38. China ADME-Tox Screening Systems, by Type USD Million (2016-2021)
  • Table 39. China ADME-Tox Screening Systems, by Application USD Million (2016-2021)
  • Table 40. China ADME-Tox Screening Systems, by Technology USD Million (2016-2021)
  • Table 41. China ADME-Tox Screening Systems, by End User USD Million (2016-2021)
  • Table 42. Japan ADME-Tox Screening Systems, by Type USD Million (2016-2021)
  • Table 43. Japan ADME-Tox Screening Systems, by Application USD Million (2016-2021)
  • Table 44. Japan ADME-Tox Screening Systems, by Technology USD Million (2016-2021)
  • Table 45. Japan ADME-Tox Screening Systems, by End User USD Million (2016-2021)
  • Table 46. India ADME-Tox Screening Systems, by Type USD Million (2016-2021)
  • Table 47. India ADME-Tox Screening Systems, by Application USD Million (2016-2021)
  • Table 48. India ADME-Tox Screening Systems, by Technology USD Million (2016-2021)
  • Table 49. India ADME-Tox Screening Systems, by End User USD Million (2016-2021)
  • Table 50. South Korea ADME-Tox Screening Systems, by Type USD Million (2016-2021)
  • Table 51. South Korea ADME-Tox Screening Systems, by Application USD Million (2016-2021)
  • Table 52. South Korea ADME-Tox Screening Systems, by Technology USD Million (2016-2021)
  • Table 53. South Korea ADME-Tox Screening Systems, by End User USD Million (2016-2021)
  • Table 54. Taiwan ADME-Tox Screening Systems, by Type USD Million (2016-2021)
  • Table 55. Taiwan ADME-Tox Screening Systems, by Application USD Million (2016-2021)
  • Table 56. Taiwan ADME-Tox Screening Systems, by Technology USD Million (2016-2021)
  • Table 57. Taiwan ADME-Tox Screening Systems, by End User USD Million (2016-2021)
  • Table 58. Australia ADME-Tox Screening Systems, by Type USD Million (2016-2021)
  • Table 59. Australia ADME-Tox Screening Systems, by Application USD Million (2016-2021)
  • Table 60. Australia ADME-Tox Screening Systems, by Technology USD Million (2016-2021)
  • Table 61. Australia ADME-Tox Screening Systems, by End User USD Million (2016-2021)
  • Table 62. Rest of Asia-Pacific ADME-Tox Screening Systems, by Type USD Million (2016-2021)
  • Table 63. Rest of Asia-Pacific ADME-Tox Screening Systems, by Application USD Million (2016-2021)
  • Table 64. Rest of Asia-Pacific ADME-Tox Screening Systems, by Technology USD Million (2016-2021)
  • Table 65. Rest of Asia-Pacific ADME-Tox Screening Systems, by End User USD Million (2016-2021)
  • Table 66. Europe ADME-Tox Screening Systems, by Country USD Million (2016-2021)
  • Table 67. Europe ADME-Tox Screening Systems, by Type USD Million (2016-2021)
  • Table 68. Europe ADME-Tox Screening Systems, by Application USD Million (2016-2021)
  • Table 69. Europe ADME-Tox Screening Systems, by Technology USD Million (2016-2021)
  • Table 70. Europe ADME-Tox Screening Systems, by End User USD Million (2016-2021)
  • Table 71. Germany ADME-Tox Screening Systems, by Type USD Million (2016-2021)
  • Table 72. Germany ADME-Tox Screening Systems, by Application USD Million (2016-2021)
  • Table 73. Germany ADME-Tox Screening Systems, by Technology USD Million (2016-2021)
  • Table 74. Germany ADME-Tox Screening Systems, by End User USD Million (2016-2021)
  • Table 75. France ADME-Tox Screening Systems, by Type USD Million (2016-2021)
  • Table 76. France ADME-Tox Screening Systems, by Application USD Million (2016-2021)
  • Table 77. France ADME-Tox Screening Systems, by Technology USD Million (2016-2021)
  • Table 78. France ADME-Tox Screening Systems, by End User USD Million (2016-2021)
  • Table 79. Italy ADME-Tox Screening Systems, by Type USD Million (2016-2021)
  • Table 80. Italy ADME-Tox Screening Systems, by Application USD Million (2016-2021)
  • Table 81. Italy ADME-Tox Screening Systems, by Technology USD Million (2016-2021)
  • Table 82. Italy ADME-Tox Screening Systems, by End User USD Million (2016-2021)
  • Table 83. United Kingdom ADME-Tox Screening Systems, by Type USD Million (2016-2021)
  • Table 84. United Kingdom ADME-Tox Screening Systems, by Application USD Million (2016-2021)
  • Table 85. United Kingdom ADME-Tox Screening Systems, by Technology USD Million (2016-2021)
  • Table 86. United Kingdom ADME-Tox Screening Systems, by End User USD Million (2016-2021)
  • Table 87. Netherlands ADME-Tox Screening Systems, by Type USD Million (2016-2021)
  • Table 88. Netherlands ADME-Tox Screening Systems, by Application USD Million (2016-2021)
  • Table 89. Netherlands ADME-Tox Screening Systems, by Technology USD Million (2016-2021)
  • Table 90. Netherlands ADME-Tox Screening Systems, by End User USD Million (2016-2021)
  • Table 91. Rest of Europe ADME-Tox Screening Systems, by Type USD Million (2016-2021)
  • Table 92. Rest of Europe ADME-Tox Screening Systems, by Application USD Million (2016-2021)
  • Table 93. Rest of Europe ADME-Tox Screening Systems, by Technology USD Million (2016-2021)
  • Table 94. Rest of Europe ADME-Tox Screening Systems, by End User USD Million (2016-2021)
  • Table 95. MEA ADME-Tox Screening Systems, by Country USD Million (2016-2021)
  • Table 96. MEA ADME-Tox Screening Systems, by Type USD Million (2016-2021)
  • Table 97. MEA ADME-Tox Screening Systems, by Application USD Million (2016-2021)
  • Table 98. MEA ADME-Tox Screening Systems, by Technology USD Million (2016-2021)
  • Table 99. MEA ADME-Tox Screening Systems, by End User USD Million (2016-2021)
  • Table 100. Middle East ADME-Tox Screening Systems, by Type USD Million (2016-2021)
  • Table 101. Middle East ADME-Tox Screening Systems, by Application USD Million (2016-2021)
  • Table 102. Middle East ADME-Tox Screening Systems, by Technology USD Million (2016-2021)
  • Table 103. Middle East ADME-Tox Screening Systems, by End User USD Million (2016-2021)
  • Table 104. Africa ADME-Tox Screening Systems, by Type USD Million (2016-2021)
  • Table 105. Africa ADME-Tox Screening Systems, by Application USD Million (2016-2021)
  • Table 106. Africa ADME-Tox Screening Systems, by Technology USD Million (2016-2021)
  • Table 107. Africa ADME-Tox Screening Systems, by End User USD Million (2016-2021)
  • Table 108. North America ADME-Tox Screening Systems, by Country USD Million (2016-2021)
  • Table 109. North America ADME-Tox Screening Systems, by Type USD Million (2016-2021)
  • Table 110. North America ADME-Tox Screening Systems, by Application USD Million (2016-2021)
  • Table 111. North America ADME-Tox Screening Systems, by Technology USD Million (2016-2021)
  • Table 112. North America ADME-Tox Screening Systems, by End User USD Million (2016-2021)
  • Table 113. United States ADME-Tox Screening Systems, by Type USD Million (2016-2021)
  • Table 114. United States ADME-Tox Screening Systems, by Application USD Million (2016-2021)
  • Table 115. United States ADME-Tox Screening Systems, by Technology USD Million (2016-2021)
  • Table 116. United States ADME-Tox Screening Systems, by End User USD Million (2016-2021)
  • Table 117. Canada ADME-Tox Screening Systems, by Type USD Million (2016-2021)
  • Table 118. Canada ADME-Tox Screening Systems, by Application USD Million (2016-2021)
  • Table 119. Canada ADME-Tox Screening Systems, by Technology USD Million (2016-2021)
  • Table 120. Canada ADME-Tox Screening Systems, by End User USD Million (2016-2021)
  • Table 121. Mexico ADME-Tox Screening Systems, by Type USD Million (2016-2021)
  • Table 122. Mexico ADME-Tox Screening Systems, by Application USD Million (2016-2021)
  • Table 123. Mexico ADME-Tox Screening Systems, by Technology USD Million (2016-2021)
  • Table 124. Mexico ADME-Tox Screening Systems, by End User USD Million (2016-2021)
  • Table 125. ADME-Tox Screening Systems: by Type(USD/Units)
  • Table 126. Company Basic Information, Sales Area and Its Competitors
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. ADME-Tox Screening Systems: by Type(USD Million)
  • Table 137. ADME-Tox Screening Systems Instruments , by Region USD Million (2022-2027)
  • Table 138. ADME-Tox Screening Systems Assay system , by Region USD Million (2022-2027)
  • Table 139. ADME-Tox Screening Systems Software , by Region USD Million (2022-2027)
  • Table 140. ADME-Tox Screening Systems: by Application(USD Million)
  • Table 141. ADME-Tox Screening Systems Discovery and Development , by Region USD Million (2022-2027)
  • Table 142. ADME-Tox Screening Systems Biopharmaceutical Production , by Region USD Million (2022-2027)
  • Table 143. ADME-Tox Screening Systems Drug Screening , by Region USD Million (2022-2027)
  • Table 144. ADME-Tox Screening Systems Tissue Engineering , by Region USD Million (2022-2027)
  • Table 145. ADME-Tox Screening Systems Others , by Region USD Million (2022-2027)
  • Table 146. ADME-Tox Screening Systems: by End User(USD Million)
  • Table 147. ADME-Tox Screening Systems Biopharmaceutical Companies , by Region USD Million (2022-2027)
  • Table 148. ADME-Tox Screening Systems Contract Research Organization (CRO’s) , by Region USD Million (2022-2027)
  • Table 149. ADME-Tox Screening Systems Academic and Research Institute , by Region USD Million (2022-2027)
  • Table 150. ADME-Tox Screening Systems Others , by Region USD Million (2022-2027)
  • Table 151. South America ADME-Tox Screening Systems, by Country USD Million (2022-2027)
  • Table 152. South America ADME-Tox Screening Systems, by Type USD Million (2022-2027)
  • Table 153. South America ADME-Tox Screening Systems, by Application USD Million (2022-2027)
  • Table 154. South America ADME-Tox Screening Systems, by Technology USD Million (2022-2027)
  • Table 155. South America ADME-Tox Screening Systems, by End User USD Million (2022-2027)
  • Table 156. Brazil ADME-Tox Screening Systems, by Type USD Million (2022-2027)
  • Table 157. Brazil ADME-Tox Screening Systems, by Application USD Million (2022-2027)
  • Table 158. Brazil ADME-Tox Screening Systems, by Technology USD Million (2022-2027)
  • Table 159. Brazil ADME-Tox Screening Systems, by End User USD Million (2022-2027)
  • Table 160. Argentina ADME-Tox Screening Systems, by Type USD Million (2022-2027)
  • Table 161. Argentina ADME-Tox Screening Systems, by Application USD Million (2022-2027)
  • Table 162. Argentina ADME-Tox Screening Systems, by Technology USD Million (2022-2027)
  • Table 163. Argentina ADME-Tox Screening Systems, by End User USD Million (2022-2027)
  • Table 164. Rest of South America ADME-Tox Screening Systems, by Type USD Million (2022-2027)
  • Table 165. Rest of South America ADME-Tox Screening Systems, by Application USD Million (2022-2027)
  • Table 166. Rest of South America ADME-Tox Screening Systems, by Technology USD Million (2022-2027)
  • Table 167. Rest of South America ADME-Tox Screening Systems, by End User USD Million (2022-2027)
  • Table 168. Asia Pacific ADME-Tox Screening Systems, by Country USD Million (2022-2027)
  • Table 169. Asia Pacific ADME-Tox Screening Systems, by Type USD Million (2022-2027)
  • Table 170. Asia Pacific ADME-Tox Screening Systems, by Application USD Million (2022-2027)
  • Table 171. Asia Pacific ADME-Tox Screening Systems, by Technology USD Million (2022-2027)
  • Table 172. Asia Pacific ADME-Tox Screening Systems, by End User USD Million (2022-2027)
  • Table 173. China ADME-Tox Screening Systems, by Type USD Million (2022-2027)
  • Table 174. China ADME-Tox Screening Systems, by Application USD Million (2022-2027)
  • Table 175. China ADME-Tox Screening Systems, by Technology USD Million (2022-2027)
  • Table 176. China ADME-Tox Screening Systems, by End User USD Million (2022-2027)
  • Table 177. Japan ADME-Tox Screening Systems, by Type USD Million (2022-2027)
  • Table 178. Japan ADME-Tox Screening Systems, by Application USD Million (2022-2027)
  • Table 179. Japan ADME-Tox Screening Systems, by Technology USD Million (2022-2027)
  • Table 180. Japan ADME-Tox Screening Systems, by End User USD Million (2022-2027)
  • Table 181. India ADME-Tox Screening Systems, by Type USD Million (2022-2027)
  • Table 182. India ADME-Tox Screening Systems, by Application USD Million (2022-2027)
  • Table 183. India ADME-Tox Screening Systems, by Technology USD Million (2022-2027)
  • Table 184. India ADME-Tox Screening Systems, by End User USD Million (2022-2027)
  • Table 185. South Korea ADME-Tox Screening Systems, by Type USD Million (2022-2027)
  • Table 186. South Korea ADME-Tox Screening Systems, by Application USD Million (2022-2027)
  • Table 187. South Korea ADME-Tox Screening Systems, by Technology USD Million (2022-2027)
  • Table 188. South Korea ADME-Tox Screening Systems, by End User USD Million (2022-2027)
  • Table 189. Taiwan ADME-Tox Screening Systems, by Type USD Million (2022-2027)
  • Table 190. Taiwan ADME-Tox Screening Systems, by Application USD Million (2022-2027)
  • Table 191. Taiwan ADME-Tox Screening Systems, by Technology USD Million (2022-2027)
  • Table 192. Taiwan ADME-Tox Screening Systems, by End User USD Million (2022-2027)
  • Table 193. Australia ADME-Tox Screening Systems, by Type USD Million (2022-2027)
  • Table 194. Australia ADME-Tox Screening Systems, by Application USD Million (2022-2027)
  • Table 195. Australia ADME-Tox Screening Systems, by Technology USD Million (2022-2027)
  • Table 196. Australia ADME-Tox Screening Systems, by End User USD Million (2022-2027)
  • Table 197. Rest of Asia-Pacific ADME-Tox Screening Systems, by Type USD Million (2022-2027)
  • Table 198. Rest of Asia-Pacific ADME-Tox Screening Systems, by Application USD Million (2022-2027)
  • Table 199. Rest of Asia-Pacific ADME-Tox Screening Systems, by Technology USD Million (2022-2027)
  • Table 200. Rest of Asia-Pacific ADME-Tox Screening Systems, by End User USD Million (2022-2027)
  • Table 201. Europe ADME-Tox Screening Systems, by Country USD Million (2022-2027)
  • Table 202. Europe ADME-Tox Screening Systems, by Type USD Million (2022-2027)
  • Table 203. Europe ADME-Tox Screening Systems, by Application USD Million (2022-2027)
  • Table 204. Europe ADME-Tox Screening Systems, by Technology USD Million (2022-2027)
  • Table 205. Europe ADME-Tox Screening Systems, by End User USD Million (2022-2027)
  • Table 206. Germany ADME-Tox Screening Systems, by Type USD Million (2022-2027)
  • Table 207. Germany ADME-Tox Screening Systems, by Application USD Million (2022-2027)
  • Table 208. Germany ADME-Tox Screening Systems, by Technology USD Million (2022-2027)
  • Table 209. Germany ADME-Tox Screening Systems, by End User USD Million (2022-2027)
  • Table 210. France ADME-Tox Screening Systems, by Type USD Million (2022-2027)
  • Table 211. France ADME-Tox Screening Systems, by Application USD Million (2022-2027)
  • Table 212. France ADME-Tox Screening Systems, by Technology USD Million (2022-2027)
  • Table 213. France ADME-Tox Screening Systems, by End User USD Million (2022-2027)
  • Table 214. Italy ADME-Tox Screening Systems, by Type USD Million (2022-2027)
  • Table 215. Italy ADME-Tox Screening Systems, by Application USD Million (2022-2027)
  • Table 216. Italy ADME-Tox Screening Systems, by Technology USD Million (2022-2027)
  • Table 217. Italy ADME-Tox Screening Systems, by End User USD Million (2022-2027)
  • Table 218. United Kingdom ADME-Tox Screening Systems, by Type USD Million (2022-2027)
  • Table 219. United Kingdom ADME-Tox Screening Systems, by Application USD Million (2022-2027)
  • Table 220. United Kingdom ADME-Tox Screening Systems, by Technology USD Million (2022-2027)
  • Table 221. United Kingdom ADME-Tox Screening Systems, by End User USD Million (2022-2027)
  • Table 222. Netherlands ADME-Tox Screening Systems, by Type USD Million (2022-2027)
  • Table 223. Netherlands ADME-Tox Screening Systems, by Application USD Million (2022-2027)
  • Table 224. Netherlands ADME-Tox Screening Systems, by Technology USD Million (2022-2027)
  • Table 225. Netherlands ADME-Tox Screening Systems, by End User USD Million (2022-2027)
  • Table 226. Rest of Europe ADME-Tox Screening Systems, by Type USD Million (2022-2027)
  • Table 227. Rest of Europe ADME-Tox Screening Systems, by Application USD Million (2022-2027)
  • Table 228. Rest of Europe ADME-Tox Screening Systems, by Technology USD Million (2022-2027)
  • Table 229. Rest of Europe ADME-Tox Screening Systems, by End User USD Million (2022-2027)
  • Table 230. MEA ADME-Tox Screening Systems, by Country USD Million (2022-2027)
  • Table 231. MEA ADME-Tox Screening Systems, by Type USD Million (2022-2027)
  • Table 232. MEA ADME-Tox Screening Systems, by Application USD Million (2022-2027)
  • Table 233. MEA ADME-Tox Screening Systems, by Technology USD Million (2022-2027)
  • Table 234. MEA ADME-Tox Screening Systems, by End User USD Million (2022-2027)
  • Table 235. Middle East ADME-Tox Screening Systems, by Type USD Million (2022-2027)
  • Table 236. Middle East ADME-Tox Screening Systems, by Application USD Million (2022-2027)
  • Table 237. Middle East ADME-Tox Screening Systems, by Technology USD Million (2022-2027)
  • Table 238. Middle East ADME-Tox Screening Systems, by End User USD Million (2022-2027)
  • Table 239. Africa ADME-Tox Screening Systems, by Type USD Million (2022-2027)
  • Table 240. Africa ADME-Tox Screening Systems, by Application USD Million (2022-2027)
  • Table 241. Africa ADME-Tox Screening Systems, by Technology USD Million (2022-2027)
  • Table 242. Africa ADME-Tox Screening Systems, by End User USD Million (2022-2027)
  • Table 243. North America ADME-Tox Screening Systems, by Country USD Million (2022-2027)
  • Table 244. North America ADME-Tox Screening Systems, by Type USD Million (2022-2027)
  • Table 245. North America ADME-Tox Screening Systems, by Application USD Million (2022-2027)
  • Table 246. North America ADME-Tox Screening Systems, by Technology USD Million (2022-2027)
  • Table 247. North America ADME-Tox Screening Systems, by End User USD Million (2022-2027)
  • Table 248. United States ADME-Tox Screening Systems, by Type USD Million (2022-2027)
  • Table 249. United States ADME-Tox Screening Systems, by Application USD Million (2022-2027)
  • Table 250. United States ADME-Tox Screening Systems, by Technology USD Million (2022-2027)
  • Table 251. United States ADME-Tox Screening Systems, by End User USD Million (2022-2027)
  • Table 252. Canada ADME-Tox Screening Systems, by Type USD Million (2022-2027)
  • Table 253. Canada ADME-Tox Screening Systems, by Application USD Million (2022-2027)
  • Table 254. Canada ADME-Tox Screening Systems, by Technology USD Million (2022-2027)
  • Table 255. Canada ADME-Tox Screening Systems, by End User USD Million (2022-2027)
  • Table 256. Mexico ADME-Tox Screening Systems, by Type USD Million (2022-2027)
  • Table 257. Mexico ADME-Tox Screening Systems, by Application USD Million (2022-2027)
  • Table 258. Mexico ADME-Tox Screening Systems, by Technology USD Million (2022-2027)
  • Table 259. Mexico ADME-Tox Screening Systems, by End User USD Million (2022-2027)
  • Table 260. ADME-Tox Screening Systems: by Type(USD/Units)
  • Table 261. Research Programs/Design for This Report
  • Table 262. Key Data Information from Secondary Sources
  • Table 263. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global ADME-Tox Screening Systems: by Type USD Million (2016-2021)
  • Figure 5. Global ADME-Tox Screening Systems: by Application USD Million (2016-2021)
  • Figure 6. Global ADME-Tox Screening Systems: by End User USD Million (2016-2021)
  • Figure 7. South America ADME-Tox Screening Systems Share (%), by Country
  • Figure 8. Asia Pacific ADME-Tox Screening Systems Share (%), by Country
  • Figure 9. Europe ADME-Tox Screening Systems Share (%), by Country
  • Figure 10. MEA ADME-Tox Screening Systems Share (%), by Country
  • Figure 11. North America ADME-Tox Screening Systems Share (%), by Country
  • Figure 12. Global ADME-Tox Screening Systems: by Type USD/Units (2016-2021)
  • Figure 13. Global ADME-Tox Screening Systems share by Players 2021 (%)
  • Figure 14. Global ADME-Tox Screening Systems share by Players (Top 3) 2021(%)
  • Figure 15. Global ADME-Tox Screening Systems share by Players (Top 5) 2021(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Hudson Robotics, Inc (United States) Revenue, Net Income and Gross profit
  • Figure 18. Hudson Robotics, Inc (United States) Revenue: by Geography 2021
  • Figure 19. ACEA Biosciences Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 20. ACEA Biosciences Inc. (United States) Revenue: by Geography 2021
  • Figure 21. Agilent Technologies, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 22. Agilent Technologies, Inc. (United States) Revenue: by Geography 2021
  • Figure 23. ADMEcell (United States) Revenue, Net Income and Gross profit
  • Figure 24. ADMEcell (United States) Revenue: by Geography 2021
  • Figure 25. Albany Molecular Research Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 26. Albany Molecular Research Inc. (United States) Revenue: by Geography 2021
  • Figure 27. BioreclamationIVT, LLC (United States) Revenue, Net Income and Gross profit
  • Figure 28. BioreclamationIVT, LLC (United States) Revenue: by Geography 2021
  • Figure 29. Beckman Coulter Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 30. Beckman Coulter Inc. (United States) Revenue: by Geography 2021
  • Figure 31. Cerep SA (France) Revenue, Net Income and Gross profit
  • Figure 32. Cerep SA (France) Revenue: by Geography 2021
  • Figure 33. Cyprotex (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 34. Cyprotex (United Kingdom) Revenue: by Geography 2021
  • Figure 35. Labcyte Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 36. Labcyte Inc. (United States) Revenue: by Geography 2021
  • Figure 37. Global ADME-Tox Screening Systems: by Type USD Million (2022-2027)
  • Figure 38. Global ADME-Tox Screening Systems: by Application USD Million (2022-2027)
  • Figure 39. Global ADME-Tox Screening Systems: by End User USD Million (2022-2027)
  • Figure 40. South America ADME-Tox Screening Systems Share (%), by Country
  • Figure 41. Asia Pacific ADME-Tox Screening Systems Share (%), by Country
  • Figure 42. Europe ADME-Tox Screening Systems Share (%), by Country
  • Figure 43. MEA ADME-Tox Screening Systems Share (%), by Country
  • Figure 44. North America ADME-Tox Screening Systems Share (%), by Country
  • Figure 45. Global ADME-Tox Screening Systems: by Type USD/Units (2022-2027)
List of companies from research coverage that are profiled in the study
  • Hudson Robotics, Inc (United States)
  • ACEA Biosciences Inc. (United States)
  • Agilent Technologies, Inc. (United States)
  • ADMEcell (United States)
  • Albany Molecular Research Inc. (United States)
  • BioreclamationIVT, LLC (United States)
  • Beckman Coulter Inc. (United States)
  • Cerep SA (France)
  • Cyprotex (United Kingdom)
  • Labcyte Inc. (United States)
Select User Access Type

Key Highlights of Report


Jul 2022 178 Pages 81 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The key segments that are playing vital role in ADME-Tox Screening Systems Market are by type [Instruments, Assay system and Software], by end use application [Discovery and Development, Biopharmaceutical Production, Drug Screening, Tissue Engineering and Others].
The ADME-Tox Screening Systems Market is gaining popularity and expected to see strong valuation by 2027.
  • Increasing Focus of Drug Manufacturer to Reduce the Development Cost of Drug with Least Toxicological Issue
  • Rising Demand for Specialized Drug due to Prevalence of various Chronic Diseases

Know More About ADME-Tox Screening Systems Report?